News Posts List
PhRMA Members Lead the World in Cancer Research Investment
09/02/2008
The medicines represent many cutting-edge approaches, including one medicine that targets and kills specific cancer cells, and then activates the patient's immune system to destroy any remaining cancer.
Germline SDHB Mutations and Familial Renal Cell Carcinoma
09/01/2008
We investigated whether germline mutations in fumarate hydratase (FH) or succinate dehydrogenase subunit genes (SDHB, SDHC, SDHD) were associated with RCC susceptibility.
Protests force review of ban on cancer drugs
08/31/2008
The National Health Service drugs rationing body has been forced to review its policy of banning life-prolonging cancer medicines that are available elsewhere in Europe.
Update: Protest goes to London
08/28/2008
A coach load of campaigners from the county met Andrew Dillon, chief executive of the National Institute for Clinical Excellence, the organisation that licenses drugs for use on the NHS.
Kidneys with small tumors okay for transplantation
08/28/2008
The availability of kidneys for transplantation could be increased by using kidneys removed for small, incidentally detected tumors, the results of an Australian study suggest.
NHS in 'meltdown' claims senior doctor
08/27/2008
He said draft guidance issued by the National Institute for Health and Clinical Excellence (Nice) to deny patients four kidney cancer drugs on the NHS was a "disgrace".
VioQuest Pharmaceuticals Announces Issuance of New U.S. Patent for Lenocta(TM)
08/27/2008
"Based on Lenocta's demonstrated anti-tumor activity against melanoma, renal cancer, prostate cancer, leukemia, and other cancers both alone and in combination with other approved immune-activation agents, including IL-2 and interferons, we believe this product candidate represents a promising approach to treating cancer,"
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
08/27/2008
In vitro inhibition of the PI3K/AKT/mTOR pathway by SF1126 was demonstrated to impede the ability of angiogenic stimulants VEGF and Bv8 to activate AKT in a dose dependant manner in two cancer cell lines (786-0 -- renal cell and PC3 prostate).
One in Four Specialists Do Not Mention Costly Drugs
08/26/2008
A total of 103 myeloma specialists in England, Wales and Scotland took part in the survey. The doctors revealed how they struggled with NHS bureaucracy and cost-cutting to obtain the best treatments for patients.
Wayne Cooper denies abusing former partner Sarah Marsh
08/26/2008
The 40-year-old said battling kidney cancer last year was "nowhere near as bad" as what she had endured in her marriage.
News Feed